biostudies-literatureUnknown52Brooks BR<h4>Background</h4>We aimed to evaluate overall survival in US patients with amyotrophic lateral sclerosis (ALS) treated with intravenous (IV) edaravone compared with those not treated with IV edaravone in a real-world setting.<h4>Methods</h4>This exploratory retrospective comparative effectiveness observational analysis included patients with ALS who were enrolled in an administrative claims database from 8 August 2017 to 31 March 2020. Propensity score matching identified IV edaravone-treated patients (cases) and non-edaravone-treated patients (controls) matched for covariates: age, race, geographic region, sex, pre-index disease duration, insurance, history of cardiovascular disease, riluzole prescription, gastrostomy tube placement, artificial nutrition, noninvasive ventilation, and alEClinicalMedicine101590https://www.ebi.ac.uk/biostudies/studies/S-EPMC9358426biostudies-literatureIntravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis.PMC9358426Liu YZhang JHagan MBrooks BRBerry JDCiepielewska MZambrano GSfalseIntravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis.<h4>Background</h4>We aimed to evaluate overall survival in US patients with amyotrophic lateral sclerosis (ALS) treated with intravenous (IV) edaravone compared with those not treated with IV edaravone in a real-world setting.<h4>Methods</h4>This exploratory retrospective comparative effectiveness observational analysis included patients with ALS who were enrolled in an administrative claims database from 8 August 2017 to 31 March 2020. Propensity score matching identified IV edaravone-treated patients (cases) and non-edaravone-treated patients (controls) matched for covariates: age, race, geographic region, sex, pre-index disease duration, insurance, history of cardiovascular disease, riluzole prescription, gastrostomy tube placement, artificial nutrition, noninvasive ventilation, and al2022-01-01T00:00:00Z2022 Oct2025-04-04T19:27:43.829Z2025-04-04T19:27:43.829ZS-EPMC93584263595851910.1016/j.eclinm.2022.101590